Photo Resource:
Pharmac has introduced new policies aimed at improving treatment access for ADHD and narcolepsy patients in New Zealand. Beginning 1 December 2024, the agency will fund the drug lisdexamfetamine (Vyvanse) for ADHD, while also eliminating the requirement for frequent specialist reviews to renew prescriptions for certain stimulant medications, simplifying ongoing access to treatment.
Simplifying Ongoing Treatment and Reducing Barriers
The new policy changes from Pharmac are aimed at reducing long-standing barriers for ADHD and narcolepsy patients in New Zealand.
The policy shift is expected to simplify ongoing treatment by removing the need for regular specialist reviews for renewals, particularly benefiting those with chronic conditions.
Support from Pharmac’s Chief Medical Officer
Dr David Hughes, Chief Medical Officer at Pharmac, explained, “This decision to fund lisdexamfetamine provides an important new treatment alternative for ADHD patients. Alongside this, we’re making it easier for people to continue their treatment by streamlining the renewal process, reducing administrative burdens for patients, clinicians, and caregivers alike.”
Positive Reactions from Advocacy Groups
Aroreretini Aotearoa and ADHD New Zealand have expressed support for the policy changes, noting that they will reduce delays and increase treatment availability for families and patients.
The updates could also allow specialists to focus on new cases, helping to improve access to psychiatric and paediatric care. This development is seen as a step forward in meeting the needs of ADHD and narcolepsy patients in New Zealand.
Strong Support from ADHD Advocacy Leaders
Kent Duston, co-convener of the ADHD policy group Aroreretini Aotearoa, expressed strong support for the recent changes.
“This is a major step forward in expanding medication options and removing obstacles for the ADHD community.
These adjustments will have a significant impact on tens of thousands of individuals,” Duston said.
He also commended Pharmac for its responsiveness, stating, “Pharmac has done an excellent job of listening to our community’s needs. We’re impressed by how quickly they’ve addressed long-standing issues and implemented practical, thoughtful solutions.”